← 產業報告目錄
Clinical Biomarkers Market Size, Share & Trends Analysis Report By Offering (Product (Efficacy Biomarker (Diagnostic Biomarker, Predictive Biomarker, Prognostic Biomarker), Safety Biomarker, Validation Biomarker), Service (Genomic Biomarker Service, Tissue Biomarker Service, Cell Service, Proteomics Service), By Clinical Area, By Technology, By End User, By Region, And By Segment Forecasts, 2024-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-01-04頁數 179報告編號 INSIGHTACE-5de534682c
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
Valued at USD 25.02 Bn as of 2023, the global Clinical Biomarkers Market is projected to climb to USD 47.25 Bn by 2031, reflecting a compound annual growth rate of 8.54% over the 2024–2031 period.
The Clinical Biomarkers sector involves molecular biomarkers that offer novel avenues for studying diseases and identifying potential new therapeutic targets. This domain has witnessed substantial transformation owing to technological breakthroughs and shifting healthcare dynamics.
Market momentum is bolstered by surging need advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
The market landscape is structured across several key segments—spanning type, application, distribution channel, and region—each contributing uniquely to overall market expansion.
Geographically, North America maintains a leading position owing to advanced infrastructure, high R&D expenditure, and a well-established regulatory environment. Meanwhile, Asia-Pacific is emerging as the fastest-growing region, bolstered by rapid industrialization and expanding end-user bases.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
The research provides an in-depth evaluation of market forces, competitive positioning, segmental dynamics, and regional trends, equipping stakeholders with actionable intelligence for the forecast period.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Clinical Biomarker Market Snapshot
Chapter 4. Global Clinical Biomarkers Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Offering Estimates & Trend Analysis
5.1. by Offering & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Offering:
5.2.1. Product
5.2.1.1. Efficacy Biomarker
5.2.1.1.1. Diagnostic Biomarker
5.2.1.1.2. Predictive Biomarker
5.2.1.1.3. Prognostic Biomarker
5.2.1.2. Safety Biomarker
5.2.1.3. Validation Biomarker
5.2.2. Service
5.2.2.1. Genomic Biomarker Service
5.2.2.2. Tissue Biomarker Service
5.2.2.3. Cell Service
5.2.2.4. Proteomics Service
Chapter 6. Market Segmentation 2: by Clinical Area Estimates & Trend Analysis
6.1. by Clinical Area & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Clinical Area:
6.2.1. Cancer Biomarkers
6.2.1.1. Breast Cancer Biomarker
6.2.1.2. Lung Cancer Biomarker
6.2.1.3. Colorectal Cancer Biomarker
6.2.1.4. Prostate Cancer Biomarker
6.2.1.5. Other
6.2.2. Cardiac Biomarkers
6.2.3. Neurological Biomarkers
6.2.4. Infectious Disease
6.2.5. Immunological Biomarkers
6.2.6. Non-Invasive Prenatal Testing
6.2.7. Other Clinical Areas
Chapter 7. Market Segmentation 3: by Technology Estimates & Trend Analysis
7.1. by Technology & Market Share, 2019 & 2031
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Technology:
7.2.1. Next-Generation Sequencing (NGS)
7.2.2. Polymerase Chain Reaction (PCR)
7.2.3. Immunohistochemistry (IHC)
7.2.4. Enzyme-Linked Immunosorbent Assay (ELISA)
7.2.5. Other Technologies
Chapter 8. Market Segmentation 4: by End User Estimates & Trend Analysis
8.1. by End User & Market Share, 2019 & 2031
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2031 for the following by End User:
8.2.1. Contract Research Organizations (CROs)
8.2.2. Research and Academic Laboratories
8.2.3. Biopharmaceutical and Biotech Companies
8.2.4. Diagnostic Centers
8.2.5. Other End Users
Chapter 9. Clinical Biomarkers Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Clinical Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Offering, 2019-2031
9.1.2. North America Clinical Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Clinical Area, 2019-2031
9.1.3. North America Clinical Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2019-2031
9.1.4. North America Clinical Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by End User, 2019-2031
9.1.5. North America Clinical Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
9.2. Europe
9.2.1. Europe Clinical Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Offering, 2019-2031
9.2.2. Europe Clinical Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Clinical Area, 2019-2031
9.2.3. Europe Clinical Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2019-2031
9.2.4. Europe Clinical Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by End User, 2019-2031
9.2.5. Europe Clinical Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
9.3. Asia Pacific
9.3.1. Asia Pacific Clinical Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Offering, 2019-2031
9.3.2. Asia Pacific Clinical Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Clinical Area, 2019-2031
9.3.3. Asia-Pacific Clinical Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2019-2031
9.3.4. Asia Pacific Clinical Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by End User, 2019-2031
9.3.5. Asia Pacific Clinical Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
9.4. Latin America
9.4.1. Latin America Clinical Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Offering, 2019-2031
9.4.2. Latin America Clinical Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Clinical Area, 2019-2031
9.4.3. Latin America Clinical Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2019-2031
9.4.4. Latin America Clinical Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by End User, 2019-2031
9.4.5. Latin America Clinical Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
9.5. Middle East & Africa
9.5.1. Middle East & Africa Clinical Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Offering, 2019-2031
9.5.2. Middle East & Africa Clinical Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Clinical Area, 2019-2031
9.5.3. Middle East & Africa Clinical Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by Technology, 2019-2031
9.5.4. Middle East & Africa Clinical Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by End User, 2019-2031
9.5.5. Middle East & Africa Clinical Biomarkers Market Revenue (US$ Million) Estimates and Forecasts by country, 2019-2031
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Abbott Laboratories
10.2.2. Agilent Technologies, Inc.
10.2.3. ALCEN
10.2.4. Arsenal Capital Partners
10.2.5. Azenta Life Sciences
10.2.6. Becton, Dickinson and Company
10.2.7. Bio-Rad Laboratories, Inc.
10.2.8. Bio Mérieux S.A.
10.2.9. BGI
10.2.10. Broad Institute
10.2.11. Charles River Laboratories
10.2.12. Caris Life Sciences
10.2.13. CENTOGENE N.V.
10.2.14. Discovery Life Sciences (DLS)
10.2.15. Enzo Biochem Inc.
10.2.16. Eurofins Scientific
10.2.17. F. Hoffmann-La Roche Ltd
10.2.18. Illumina, Inc.
10.2.19. Myriad Genetics, Inc.
10.2.20. NeoGenomics Laboratories
10.2.21. Novogene Co., Ltd.
10.2.22. Personalis Inc.
10.2.23. QIAGEN N.V.
10.2.24. Quest Diagnostics Incorporated
10.2.25. Q2 Solutions
10.2.26. Thermo Fisher Scientific Inc.
10.2.27. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們